Description

TheCultrex®SpheroidInvasionMatrixisaproprietaryextracellularmatrixblendcomprisedofbasementmembraneextract,derivedfrommurineEHSsarcomacells,andcollagenI,frombovineextensortendons.Thismatrixformsahydrogelnetworkonwhichinvasivecellscantraveloutofapreformedspheroid.Cellinvasionisvisualizedmicroscopicallyandcanbequantifiedthroughimageanalysissoftware.

Qualitycontrolspecifications:

• Mousecoloniesareroutinelyscreenedforpathogensusing mouseantibodyproduction(MAP)testing.
• Engelbreth-Holm-Swarm(EHS)tumorisLDEV-free.
• PathClear®–testednegativebyPCRfor17bacterialandvirusstrainstypicallyincludedinmouseantibodyproduction(MAP)testing,plus13additionalmurineinfectiousagentsincludingLDEV,foratotalof31organismsandviruses.
• Nobacterialorfungalgrowthdetectedafterincubationat37°Cfor14daysfollowingUSPsterilitytestingguidelines.
• Endotoxinconcentration≤8EU/mlbyLimulusAmoebocyteLysate(LAL)assay.
• NomycoplasmacontaminationdetectedbyPCR.
• ProvidedinDulbecco’sModifiedEagle’smedium(DMEM)withoutphenolred,with10µg/mlgentamicinsulfate.
• BIOLOGicalactivitydeterminedforeachlot:
  • PerformancetestedinCultrex®3DSpheroid CellInvasionAssay.

Trevigen公司位于美国马里兰州的高科技走廊，是一家有12年历史、成长迅速的生物技术公司，其产品和技术的发展方向主要在癌症研究领域，重点强调细胞凋亡、DNA损伤和修复，以及癌症细胞功能和行为。Trevigen品牌的分销商遍及北美，欧洲和环太平洋地区。关于DNA的损伤分析技术的研究，Trevigen获得美国国立卫生研究院（NIH）的SBIR项目资助。